Esperion Therapeutics Azioni (NASDAQ: ESPR)

Ultime notizie per Esperion Therapeutics (NASDAQ:ESPR) Azioni

Esperion Therapeutics

Esperion Therapeutics Inc is a pharmaceutical company. It specializes in developing and commercializing accessible, oral, once-daily, non-statin medicines for patients struggling with elevated low-density lipoprotein cholesterol. The firm has the business of researching, developing and commercializing therapies for the treatment of patients with the elevated low-density lipoprotein cholesterol operating segment. Its products include NEXLETOL, NEXLIZET, NILEMDO and NUSTENDI. The Company manages its business in one operating segment, which is the business of researching, developing and commercializing therapies for the treatment of patients with elevated LDL-C.

Esperion Therapeutics, Inc. - Common Stock

Esperion Therapeutics Inc

ESPRE TECHNOLOGIES INC B by ESPRE TECHNOLOGIES INC

Espre Technologies Inc

ESPRIT HOLDINS LTD by Esprit Holdings Ltd.

Esprit Holdings Ltd

ESPRIT HLDGS S/ADR by Esprit Holdings Ltd.

HC Wainwright &amp; Co. analyst Joseph Pantginis reiterates Esperion Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ESPR#NASDAQ">ESPR</a>) with a Buy and maintains $16 price target.

News

Price Target

Reiteration

Analyst Ratings

ESPR

HC Wainwright & Co. Reiterates Buy on Esperion Therapeutics, Maintains $16 Price Target

– An Exploratory Analysis Reports Patients with PAD Who Took Bempedoic Acid Were 36% Less Likely to Experience a Major Adverse Limb Event Compared to Placebo –
ANN ARBOR, Mich., Nov. 18, 2024 (GLOBE NEWSWIRE) -- Esperion (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ESPR#NASDAQ">ESPR</a>) today announced the presentation of an analysis from the CLEAR Outcomes study focused on patients with Peripheral Artery Disease (PAD) who were unable or unwilling to take statin medications. These data were presented today in an oral featured science presentation at the 2024 American Heart Association (AHA) Scientific Sessions, which took place from November 16-18, 2024, in Chicago, IL. Additionally, two exploratory analyses from the CLEAR Outcomes trial and a real-world analysis of bempedoic acid usage were presented at the conference.

Biotech

General

Esperion Highlights New Exploratory Data From CLEAR Outcomes Trial Highlighting Value Of NEXLETOL In Oral Featured Science Session And Multiple Poster Presentations At AHA Scientific Sessions 2024; Exploratory Analysis Reports Patients With PAD Who Took Bempedoic Acid Were 36% Less Likely To Experience A Major Adverse Limb Event Compared To Placebo

WIIM

Esperion Therapeutics shares are trading higher. The stock may be moving on continued strength after reporting better-than-expected Q3 financing results yesterday. Also, HC Wainwright & Co. reiterated a Buy rating on the stock.

<h3>Gainers</h3>
<ul>
<li>Ensysce Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENSC#NASDAQ">ENSC</a>) shares rose 31.7% to $0.72 during Thursday's pre-market session. The company's market cap stands at $10.8 million. </li>
<li>VSee Health (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VSEE#NASDAQ">VSEE</a>) stock increased by 24.03% to $1.6. The market value of their outstanding shares is at $24.5 million. </li>
<li>Emergent BioSolutions (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EBS#NYSE">EBS</a>) shares increased by 22.93% to $11.31. The company's market cap stands at $592.6 million. As per the press release, Q3 earnings came out yesterday. </li>
<li>LogicMark (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LGMK#NASDAQ">LGMK</a>) stock rose 20.4% to $0.12. The company's market cap stands at $1.3 million. </li>
<li>China Pharma Holdings, Inc. Common Stock (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/CPHI#AMEX">CPHI</a>) stock increased by 18.14% to $0.26. </li>
<li>Syra Health (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SYRA#NASDAQ">SYRA</a>) stock rose 17.25% to $0.49. The company's market cap stands at $4.8 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Sutro Biopharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STRO#NASDAQ">STRO</a>) shares decreased by 15.5% to $3.5 during Thursday's pre-market session. The company's market cap stands at $286.8 million. </li>
<li>Plus Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PSTV#NASDAQ">PSTV</a>) shares decreased by 14.69% to $1.22. The market value of their outstanding shares is at $7.1 million. </li>
<li>Clover Health Investments (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLOV#NASDAQ">CLOV</a>) stock decreased by 9.89% to $3.92. The market value of their outstanding shares is at $1.9 billion. As per the press release, Q3 earnings came out yesterday. </li>
<li>Esperion Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ESPR#NASDAQ">ESPR</a>) shares fell 9.51% to $2.0. The market value of their outstanding shares is at $392.4 million. As per the news, the Q3 earnings report came out today. </li>
<li>Personalis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PSNL#NASDAQ">PSNL</a>) stock fell 9.14% to $5.07. The company's market cap stands at $334.2 million. As per the news, the Q3 earnings report came out yesterday. </li>
<li>SenesTech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNES#NASDAQ">SNES</a>) stock decreased by 8.78% to $2.6. The market value of their outstanding shares is at $2.6 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Movers

CLOV

CPHI

ENSC

LGMK

PSNL

PSTV

SNES

STRO

SYRA

VSEE

12 Health Care Stocks Moving In Thursday's Pre-Market Session

<h3>Gainers</h3>
<ul>
<li>Ensysce Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENSC#NASDAQ">ENSC</a>) stock rose 31.7% to $0.72 during Thursday's pre-market session. The market value of their outstanding shares is at $10.8 million. </li>
<li>VSee Health (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VSEE#NASDAQ">VSEE</a>) shares rose 24.03% to $1.6. The company's market cap stands at $24.5 million. </li>
<li>Emergent BioSolutions (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EBS#NYSE">EBS</a>) shares rose 22.93% to $11.31. The market value of their outstanding shares is at $592.6 million. As per the press release, Q3 earnings came out yesterday. </li>
<li>LogicMark (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LGMK#NASDAQ">LGMK</a>) shares rose 20.4% to $0.12. The market value of their outstanding shares is at $1.3 million. </li>
<li>China Pharma Holdings, Inc. Common Stock (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/CPHI#AMEX">CPHI</a>) shares moved upwards by 18.14% to $0.26. </li>
<li>Syra Health (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SYRA#NASDAQ">SYRA</a>) shares increased by 17.25% to $0.49. The company's market cap stands at $4.8 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Sutro Biopharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STRO#NASDAQ">STRO</a>) stock fell 15.5% to $3.5 during Thursday's pre-market session. The market value of their outstanding shares is at $286.8 million. </li>
<li>Plus Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PSTV#NASDAQ">PSTV</a>) stock declined by 14.69% to $1.22. The company's market cap stands at $7.1 million. </li>
<li>Clover Health Investments (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLOV#NASDAQ">CLOV</a>) shares declined by 9.89% to $3.92. The company's market cap stands at $1.9 billion. As per the news, the Q3 earnings report came out yesterday. </li>
<li>Esperion Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ESPR#NASDAQ">ESPR</a>) shares declined by 9.51% to $2.0. The company's market cap stands at $392.4 million. As per the news, the Q3 earnings report came out today. </li>
<li>Personalis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PSNL#NASDAQ">PSNL</a>) stock fell 9.14% to $5.07. The company's market cap stands at $334.2 million. The company's, Q3 earnings came out yesterday. </li>
<li>SenesTech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNES#NASDAQ">SNES</a>) shares fell 8.78% to $2.6. The company's market cap stands at $2.6 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Esperion Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ESPR#NASDAQ">ESPR</a>) reported quarterly losses of $(0.15) per share which beat the analyst consensus estimate of $(0.17) by 11.76 percent. The company reported quarterly sales of $51.63 million which beat the analyst consensus estimate of $51.32 million by 0.61 percent. This is a 52.00 percent increase over sales of $33.97 million the same period last year.

Earnings

Esperion Therapeutics Q3 2024 GAAP EPS $(0.15) Beats $(0.17) Estimate, Sales $51.63M Beat $51.32M Estimate

Esperion Therapeutics shares are trading higher after the company announced that its European partner, Daiichi Sankyo Europe, reported final 2-year follow-up data from the German cohort of the multinational, European observational MILOS study.

– Patients Prescribed Bempedoic Acid, As Well As Bempedoic Acid and Ezetimibe, With or Without Other Lipid Lowering Therapies, Showed A One-Third Relative Reduction in Low-Density LDL-C From Pre-Treatment To 2-Years in the MILOS Study –
– Real-World Results Demonstrated ~7-Fold Increase in Proportion of Patients Achieving LDL-C Goals When Treated With Bempedoic Acid or Bempedoic Acid and Ezetimibe –
– Data From the MILOS German Cohort Showed Bempedoic Acid, Alone or With Ezetimibe, Was Effective and Had A Safety Profile in Real-World Settings Consistent With the CLEAR Outcomes Study –
ANN ARBOR, Mich., Oct. 02, 2024 (GLOBE NEWSWIRE) -- Esperion (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ESPR#NASDAQ">ESPR</a>) today announced that its European partner, Daiichi Sankyo Europe (DSE), reported final 2-year follow-up data from the German cohort of the multinational, European observational MILOS study. The European study evaluated the real-world use of bempedoic acid, marketed as NILEMDO&#xAE;&nbsp;in the EU and bempedoic acid and ezetimibe, marketed as NUSTENDI&#xAE; in the EU, in patients with primary hypercholesterolemia or mixed dyslipidemia. The products are marketed as NEXLETOL&#xAE; (bempedoic acid) and NEXLIZET&#xAE;&nbsp;(bempedoic acid and ezetimibe) in the U.S.
The results, presented in Hamburg, Germany at DGK Herztage 2024, demonstrated the effectiveness and safety profile of bempedoic acid, both alone and in combination with other lipid-lowering therapies (LLTs) in clinical practice. Raised LDL-C is a key modifiable contributor to risk of major cardiovascular events, with studies showing that every 1 mmol/L reduction in LDL-C is associated with a 22% reduction in major cardiovascular events after one year.
The German cohort of the MILOS study comprising 973 patients from 125 sites in Germany, is one of the most comprehensive assessments of bempedoic acid in a real-world clinical setting to-date in Germany.&nbsp;Patients were followed-up for two years, with LDL-C levels assessed at pre-treatment, one year (1Y) and two years (2Y). Overall, 638 of 973 patients (65.6%) completed 2Y follow up, with LDL-C values at pre-treatment, 1Y and 2Y available for 451 patients. In these 451 patients, a mean reduction of LDL-C levels from 3.1 mmol/L (121.4 mg/dL) at pre-treatment, to 2.0 mmol/L (77.2 mg/dL) was observed, representing an average relative reduction of 30.3% in the overall population.
Additionally, the percentage of patients reaching their LDL-C goals increased from 4.9% at pre-treatment to 35.3% at the 2Y follow-up – an approximately 7-fold increase.&nbsp;The proportions of high-risk and very high-risk patients reaching LDL-C goals increased from 5.6% to 32.5%, and 3.6% to 35.2%, respectively.
Overall, more than 80% of patients received bempedoic acid in combination with other LLTs at pre-treatment and 2Y, including statins and ezetimibe. The safety profile of bempedoic acid in this real-world population was assessed at 1Y and 2Y and was consistent with that observed in the CLEAR clinical trial program.&nbsp;

Esperion EU Partner Reports Final Real-World Results From MILOS German Cohort Demonstrating Strong Increase In LDL-C Goal Achievement With Addition Of Bempedoic Acid

– New Additions to Medicare Formularies at Optum/United AARP and CVS/SilverScript Coupled with Humana Provides Access to More Than 65% of Medicare Insured Lives and More Than 92% of Commercially Insured Lives – &nbsp;
– Increased Coverage and Improved Prior Authorization Processes Make Prescribing NEXLETOL and NEXLIZET Easier for Healthcare Providers –
– NEXLETOL and NEXLIZET are the Only Non-Statins FDA Approved to Lower LDL Cholesterol and Reduce Risk of Myocardial Infarction and Coronary Revascularization in Both Primary and Secondary Prevention Patients –
ANN ARBOR, Mich., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Esperion today announced that NEXLETOL&#xAE; (bempedoic acid) and NEXLIZET&#xAE; (bempedoic acid and ezetimibe) have achieved additional coverage on national and large regional formularies since the U.S. Food and Drug Administration's (FDA) approval of the expanded indications, increasing total coverage to more than 136 million commercially insured lives (92% of all commercial lives) and 34 million Medicare lives (65% of all Medicare lives). Additionally, many payers have accelerated alignment of utilization management criteria since the FDA approval of the expanded indications to the new labels.
 &nbsp;

Esperion Secures Additional Commercial And Medicare Formulary Coverage For NEXLETOL And NEXLIZET; New Additions To Medicare Formularies At Optum/United AARP And CVS/SilverScript Coupled With Humana Provides Access To More Than 65% Of Medicare Insured Lives And More Than 92% Of Commercially Insured Lives

Needham analyst Serge Belanger maintains Esperion Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ESPR#NASDAQ">ESPR</a>) with a Buy and lowers the price target from $8 to $6.

Needham Maintains Buy on Esperion Therapeutics, Lowers Price Target to $6

Shares of Ainos, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AIMD#NASDAQ">AIMD</a>) rose sharply in today's pre-market trading after the company announced that it has obtained exclusive licenses for a total of 10 invention patents and patent applications from Taiwan Carbon Nano Technology.
Ainos shares jumped 37.7% to $0.7200 in pre-market trading.
Here are some other stocks moving in pre-market trading.
<h3 class="wp-block-heading">Gainers</h3>
<ul>
<li>LogicMark, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LGMK#NASDAQ">LGMK</a>) rose 49% to $0.3201 in today's pre-market trading. On Aug. 5, LogicMark announced the closing of $4.5 million public offering priced at-the-market.</li>
<li>PS International Group Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PSIG#NASDAQ">PSIG</a>) gained 27.7% to $1.29 in pre-market trading after jumping 46% on Friday.</li>
<li>Y-mAbs Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/YMAB#NASDAQ">YMAB</a>) shares rose 27.3% to $14.28 in pre-market trading.</li>
<li>FSD Pharma Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HUGE#NASDAQ">HUGE</a>) gained 24.5% to $0.2490 in pre-market trading. FSD Pharma shares jumped 118% on Friday after Celly Nutrition, which is backed by FSD Pharma, announced the upcoming launch of its &#8216;unbuzzd&#8217; recovery drink.</li>
<li>Genius Group Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GNS#NYSE">GNS</a>) gained 18.5% to $0.16. Genius Group shares gained around 8% on Friday after the company announced its board approved the purchase of up to 10 million shares by founder and CEO Roger James Hamilton.</li>
<li>ProMIS Neurosciences, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PMN#NASDAQ">PMN</a>) gained 15.4% to $1.41 in pre-market trading. The company, last week, posted a narrower-than-expected quarterly loss.</li>
<li>Adaptimmune Therapeutics plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADAP#NASDAQ">ADAP</a>) jumped 12.8% to $1.12 in pre-market trading.</li>
<li>Esperion Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ESPR#NASDAQ">ESPR</a>) gained 11.4% to $2.25 in pre-market trading.</li>
<li>AirNet Technology Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANTE#NASDAQ">ANTE</a>) shares gained 10.1% to $0.2999 in pre-market trading after declining around 20% on Friday.</li>
</ul>
<h3 class="wp-block-heading">Losers</h3>
<ul>
<li>Meta Materials Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MMAT#NASDAQ">MMAT</a>) shares declined 27.7% to $0.6810 in pre-market trading. Meta Materials shares dipped around 55% on Friday after the company disclosed in an SEC filing that it ceased operations and filed a voluntary petition for relief under the provisions of Chapter 7 of Title 11 in the US Bankruptcy Court.</li>
<li>iLearningEngines, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AILE#NASDAQ">AILE</a>) shares dipped 25.8% to $4.29 in pre-market trading. ILearningEngines will report financial results for the second quarter before the opening bell on Tuesday, Aug. 13.</li>
<li>Tenon Medical, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TNON#NASDAQ">TNON</a>) declined 16.9% to $0.49 in pre-market trading. Tenon Medical will release financial results for the second quarter after the closing bell on Aug. 13.</li>
<li>Sonoma Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNOA#NASDAQ">SNOA</a>) shares declined 15.4% to $0.21 in pre-market trading. Sonoma Pharmaceuticals shares dipped around 20% on Friday after the company reported worse-than-expected first-quarter financial results.</li>
<li>Humacyte, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HUMA#NASDAQ">HUMA</a>) shares fell 13.4% to $6.85 in pre-market trading after the company announced that the FDA will require additional time to complete its review of the BLA for ATEV in the treatment of vascular trauma.</li>
<li>Big Tree Cloud Holdings Limited  (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DSY#NASDAQ">DSY</a>) shares fell 11.6% to $1.30 in pre-market trading after jumping 70% on Friday.</li>
<li>ENDRA Life Sciences Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NDRA#NASDAQ">NDRA</a>) fell 11.1% to $0.0448 in pre-market trading. ENDRA Life Sciences will report financial results for the three and six months ended June 30 on Wednesday, Aug. 14.</li>
<li>CareMax, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CMAX#NASDAQ">CMAX</a>) fell 7.7% to $4.19 in today's pre-market trading after the company reported worse-than-expected second-quarter results.</li>
<li>Hawaiian Electric Industries, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HE#NYSE">HE</a>) fell 7.7% to $14.28 pre-market trading after the company reported weak second-quarter earnings.</li>
<li>Pagaya Technologies Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PGY#NASDAQ">PGY</a>) shares fell 6% to $13.37 in pre-market trading. The company reported second-quarter results on Friday.</li>
</ul>
Now Read This:<a href="https://www.benzinga.com/markets/24/08/40298443/wall-streets-most-accurate-analysts-give-their-take-on-3-defensive-stocks-delivering-high-dividend-y"> </a>
<ul>
<li><a href="https://www.benzinga.com/markets/24/08/40298443/wall-streets-most-accurate-analysts-give-their-take-on-3-defensive-stocks-delivering-high-dividend-y">Wall Street&#8217;s Most Accurate Analysts Give Their Take On 3 Defensive Stocks Delivering High-Dividend Yields</a></li>
</ul>

Pre-Market Outlook

Markets

Trading Ideas

ADAP

AILE

AIMD

ANTE

CMAX

MASSIVE INTERACTIVE NV by Massive Interactive, Inc.

HUGE

HUMA

MMAT

NDRA

PSIG

SNOA

TNON

YMAB

Why Ainos Shares Are Trading Higher By Around 38%; Here Are 20 Stocks Moving Premarket

Guidance

Health Care

Esperion Reiterates Its Full Year 2024 Operating Expense Guidance Of Approximately $225M-$245M, Including $20M In Non-cash Expenses Related To Stock Compensation

Esperion Therapeutics Q2 2024 GAAP EPS $(0.33) Misses $(0.18) Estimate, Sales $73.834M May Not Be Comparable To $49.056M Estimate

Needham analyst Serge Belanger reiterates Esperion Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ESPR#NASDAQ">ESPR</a>) with a Buy and maintains $8 price target.

Needham Reiterates Buy on Esperion Therapeutics, Maintains $8 Price Target

Esperion Therapeutics shares are trading lower after the company announced that it entered into a Royalty Purchase Agreement with OMERS Life Sciences. The stock initially traded higher, but it has since reversed.

Esperion Therapeutics shares are trading higher after the company announced that it entered into a Royalty Purchase Agreement with OMERS Life Sciences.

Esperion Therapeutics Q3 2024 Earnings Preview

Analyst Joseph Pantginis of H.C. Wainwright maintained a Buy rating on Esperion (ESPR – Research Report), retaining the price target of $16.00. Jos...

Esperion's Strong Financial Performance and Strategic Expansion Drive Buy Rating

Analyst Serge Belanger of Needham maintained a Buy rating on Esperion (ESPR – Research Report), retaining the price target of $6.00. Serge Belanger...

Esperion's Expanded Medicare Coverage and Revenue Growth Make It a Compelling Buy

Analyst Jason Butler from JMP Securities reiterated a Buy rating on Esperion (ESPR – Research Report) and keeping the price target at $7.00. Jason ...

Esperion's Global Expansion and Strong Financial Outlook Justify Buy Rating

Esperion (ESPR – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Jason Zemansky from Ban...

Esperion's Growth Challenges: Sell Rating Maintained Amid Market Pressures and Competitive Threats

Esperion Therapeutics: Growth Initiatives Are Paying Off - Buy

Gradually lowering inflation and reducing borrowing rates have opened new and exciting doors for growth stocks. With a positive economic outlook, investors could keep a watchful eye on Esperion Therapeutics (ESPR), AngioDynamics (ANGO), and Fathom Holdings (FTHM) to capitalize on the growing economy. Continue Reading… With the recent Fed rate cut, slowly easing rate of inflation, and general optimism for economic growth, U.S. businesses are showing signs of strong growth prospects. Thus, it might be an opportune moment to seek high-growth stocks.
With these economic drivers in mind, investors could look into shares of growth stocks Esperion Therapeutics, Inc. (<a href="https://stocknews.com/stock/ESPR/">ESPR</a>), AngioDynamics, Inc. (<a href="https://stocknews.com/stock/ANGO/">ANGO</a>), and Fathom Holdings Inc. (<a href="https://stocknews.com/stock/FTHM/">FTHM</a>). All three stocks are priced under $10, and Wall Street analysts see substantial upsides in them.
The Federal Reserve cut its key interest rate by a quarter-point this month in response to the steady decline in the once-high inflation. A historic half-point reduction in September preceded this rate cut. The <a href="https://apnews.com/article/federal-reserve-election-inflation-trump-economy-prices-e6b837fd85cff5ad71d4e40939b97237">benchmark rate sits around 4.6%</a> right now, down from a four-decade high of 5.3%.
These rate cuts mainly aimed to combat inflation and reduce borrowing costs for consumers and businesses alike. Inflation has since fallen from a 9.1% peak in mid-2022 to a three-and-a-half-year low of <a href="https://apnews.com/article/inflation-prices-interest-rates-economy-federal-reserve-cd6d9712bfd484d6e1bc4ccb958dcf23">2.4% in September</a>. As inflation eases, the economy gets another chance to start thriving again.
The Fed plans to cut the rates once more this year and around four times in 2025 to bring inflation closer to its 2% target. However, with the economy mostly solid and Wall Street anticipating faster growth, further rate cuts may become less likely.
In this dynamic environment, growth stocks stand out for their above-average revenue growth, with companies frequently reinvesting profits to drive future expansion, making them a compelling choice for long-term investors.
Now, let us dive deep into the fundamentals of three growth stocks.
Esperion Therapeutics, Inc. (<a href="https://stocknews.com/stock/ESPR/">ESPR</a>)
ESPR is a pharmaceutical company that focuses on developing and commercializing medicines for patients suffering from elevated low-density lipoprotein cholesterol (LDL-C). Its offerings include NEXLETOL, NEXLIZET, NILEMDO, and NUSTENDI.
On May 22, ESPR and Daiichi Sankyo Europe GmbH announced the approval of NILEMDO&#xAE; and NUSTENDI&#xAE;, the European Commission (EC), for treating hypercholesterolemia and reducing the risk of adverse cardiovascular events. ESPR is set to have a significant presence in the European drug market for treating cardiac diseases and enabling newer revenue streams for the company.
For the fiscal 2024 third quarter ended September 30, ESPR's total revenues increased 52% year-over-year to $51.63 million. As of September 30, 2024, the company's cash and cash equivalents stood at $144.72 million, compared to $82.25 million on December 31, 2023.
Moreover, ESPR's total assets stood at $314.11 as of September 30, 2024, compared to $205.80 on December 31, 2023.
Analysts expect ESPR's revenue for the fiscal year ending December 2025 to increase 31.3% year-over-year to $427.99 million. Moreover, its <a href="https://www.investopedia.com/terms/e/eps.asp">EPS</a> for the same period is expected to increase significantly to $0.20. Moreover, the company topped the consensus revenue and EPS estimates in three of its four trailing quarters.
Over the past three years, ESPR's revenue and total assets have grown at CAGRs of 59.6% and 11.7%, respectively.
Shares of ESPR have surged 23.9% over the past three months and 135.9% over the past year to close the last trading session at $2.23.
Based on four Wall Street analysts offering 12-month price targets for ESPR in the last three months, the average target price is $7.76, <a href="https://www.tipranks.com/stocks/espr/forecast">indicating a 248% upside</a> from the last price.
ESPR's robust fundamentals are reflected in its <a href="https://stocknews.com/powr-ratings/">POWR Ratings</a>. The stock has an overall rating of B, which translates to a Buy in our proprietary rating system. The POWR Ratings are calculated by considering 118 different factors, each weighted to an optimal degree.
ESPR has a B grade for Growth, Value, and Quality. It is ranked #46 out of 332 stocks in the <a href="https://stocknews.com/category/biotech/">Biotech</a> industry.
<a href="https://stocknews.com/stock/ESPR/">Click here</a> to access ESPR's ratings for Stability, Momentum, and Sentiment.
AngioDynamics, Inc. (<a href="https://stocknews.com/stock/ANGO/">ANGO</a>)
ANGO is a medical technology company that designs, manufactures, and sells medical, surgical, and diagnostic devices for vascular access, peripheral vascular disease treatment, oncology, and surgical settings. Its products include oncology products like Model 1500X RF Generator, Alatus, VenaCure EVLT 1470 Pro Laser, etc.
On May 21, ANGO announced the European CE Mark approval of its AlphaVac F1885 System for the non-surgical removal of thrombi or emboli from the pulmonary arteries and the treatment of pulmonary embolism (PE). This approval broadened ANGO's reach into the European markets and established the company as one of the market leaders in the treatment of PE.
For the fiscal 2025 first quarter that ended on August 31, 2024, ANGO's net sales came in at $67.49 million. Its gross profit was reported to be $36.72 million.
Street expects ANGO's revenue to increase 7.7% year-over-year to $305.80 million for the fiscal year ending May 2026. Moreover, the company has surpassed consensus EPS estimates in three of its four trailing quarters.
Over the past three years, the company's tangible book value has grown at a 22.6% CAGR over the past three years. ANGO's shares have gained 14.2% over the past six months and 16.9% over the past nine months, closing the last trading session at $6.99.
Based on three Wall Street analysts offering 12-month price targets for ANGO in the last three months, the average target price is $13, <a href="https://www.tipranks.com/stocks/ango/forecast">indicating an 86% upside</a> from the last price.
ANGO's fundamentals are mirrored in its POWR Ratings. It has a B grade in Growth and Sentiment.
ANGO is ranked #81 out of 137 stocks in the <a href="https://stocknews.com/category/medical-devices-equipment/">Medical - Devices &amp; Equipment</a> industry.
<a href="https://stocknews.com/stock/ANGO/">Click here</a> to access ANGO's ratings for Value, Momentum, Stability, and Quality.
Fathom Holdings Inc. (<a href="https://stocknews.com/stock/FTHM/">FTHM</a>)
FTHM offers a technology-driven real estate services platform for residential brokerage, mortgage, title, insurance, and Software as a Service to brokerages and agents through its cloud-based software, intelliAgent. The company's three operational segments include: Real Estate Brokerage; Mortgage; and Technology.
On November 4, FTHM announced the acquisition of My Home Group, a leading Arizona-based brokerage ranked 27th in the nation by transaction volume. The acquisition expands Fathom's market reach, strengthens its agent network, and supports its commitment to delivering comprehensive real estate solutions nationwide.
For the fiscal 2024 third quarter that ended on September 30, FTHM's total revenue came in at $83.73 million. As of September 30, 2024, FTHM's cash and cash equivalents were reported to be $13.10 million, compared to $7.40 million on December 31, 2024.
The consensus revenue estimate of $408.92 million for the fiscal year ending December 2025 reflects a year-over-year rise of 25.6%.
Over the past five years, the company's revenue and total assets have grown at CAGRs of 27% and 91.8%, respectively. FTHM shares have gained 36.2% over the past six months, closing the last trading session at $1.92.
Based on two Wall Street analysts offering 12-month price targets for FTHM in the last three months, the average target price is $3.75, <a href="https://www.tipranks.com/stocks/fthm/forecast">indicating a 95.3% upside</a> from the last price.
FTHM's sound prospects are projected in its POWR Ratings. It has a B grade for Growth.
FTHM is ranked #32 out of 46 stocks in the <a href="https://stocknews.com/category/real-estate-services/">Real Estate Services</a> industry.
<a href="https://stocknews.com/stock/FTHM/">Click here</a> to access FTHM's ratings for Value, Stability, Quality, Momentum, and Sentiment.
What To Do Next?
Get your hands on this special report with 3 low priced companies with tremendous upside potential even in today's volatile markets:
<a href="https://report.stocknews.com/free-report/3stocks/?formplacement=artbotad_3s">3 Stocks to DOUBLE This Year &gt;</a>

<hr />
ESPR shares were trading at $2.19 per share on Thursday afternoon, down $0.04 (-1.79%). Year-to-date, ESPR has declined -26.76%, versus a 26.35% rise in the benchmark S&amp;P 500 index during the same period.
<hr><div style="clear:both;"></div> <h2>About the Author: Anushka Dutta</h2> <img src='https:/wp-content/uploads/2021/08/Anushka-Dutta_Headshot_3.jpg' style="float:left; padding:5px;width:125px;">Anushka is an analyst whose interest in understanding the impact of broader economic changes on financial markets motivated her to pursue a career in investment research.<a href="https://stocknews.com/authors/?author=anushka-dutta">More...</a>The post <a href=https://stocknews.com/news/espr-ango-fthm-3-growth-stocks-under-10-that-analysts-predict-will-skyrocket/>3 Growth Stocks Under $10 That Analysts Predict Will Skyrocket</a> appeared first on <a href=https://stocknews.com/>StockNews.com</a>

3 Growth Stocks Under $10 That Analysts Predict Will Skyrocket

Esperion (ESPR) announced the presentation of an analysis from the CLEAR Outcomes study focused on patients with Peripheral Artery Disease who were...

Esperion highlights exploratory data from CLEAR outcomes trial of Nexletol

Esperion (ESPR – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Joseph Pantginis from H.C. ...

Buy Rating Affirmed for Esperion Due to Bempedoic Acid's Clinical Efficacy in Recent Trials

ANGO

FTHM

Press Releases

Esperion to Participate in Upcoming 2024 Cantor Global Healthcare Conference

Esperion Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

Esperion EU Partner Reports Final Real-World Results from MILOS German Cohort Demonstrating Strong Increase in LDL-C Goal Achievement With Addition of Bempedoic Acid

Esperion to Report Third Quarter 2024 Financial Results on November 7

Esperion Announces a Featured Presentation in the Late Breaker/Featured Science Track and Three Poster Presentations Accepted for the 2024 American Heart Association (AHA) Scientific Sessions

Esperion to Participate in Upcoming Jefferies London Healthcare Conference

Esperion Reports Third Quarter 2024 Financial Results and Provides a Business Update

Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Esperion Highlights New Exploratory Data from CLEAR Outcomes Trial Highlighting Value of NEXLETOL® (bempedoic acid) in Oral Featured Science Session and Multiple Poster Presentations at AHA Scientific Sessions 2024

Comments

Esperion Therapeutics

Notizie

Ultime notizie per Esperion Therapeutics (NASDAQ:ESPR) Azioni

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO